中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

转录激活因子3与慢性肝脏疾病相关性的研究进展

辜群利 李晖 邓秀秀 曾子键 董海舰

辜群利, 李晖, 邓秀秀, 等. 转录激活因子3与慢性肝脏疾病相关性的研究进展[J]. 临床肝胆病杂志, 2021, 37(9): 2236-2240. DOI: 10.3969/j.issn.1001-5256.2021.09.047
引用本文: 辜群利, 李晖, 邓秀秀, 等. 转录激活因子3与慢性肝脏疾病相关性的研究进展[J]. 临床肝胆病杂志, 2021, 37(9): 2236-2240. DOI: 10.3969/j.issn.1001-5256.2021.09.047
GU QL, LI H, DENG XX, et al. Research advances in the association between activating transcription factor 3 and chronic liver diseases[J]. J Clin Hepatol, 2021, 37(9): 2236-2240. DOI: 10.3969/j.issn.1001-5256.2021.09.047
Citation: GU QL, LI H, DENG XX, et al. Research advances in the association between activating transcription factor 3 and chronic liver diseases[J]. J Clin Hepatol, 2021, 37(9): 2236-2240. DOI: 10.3969/j.issn.1001-5256.2021.09.047

转录激活因子3与慢性肝脏疾病相关性的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.09.047
基金项目: 

四川省科技厅重点研发项目 20ZDYF2153

详细信息
    通讯作者:

    李晖, 1400124746@qq.com

  • 中图分类号: R575

Research advances in the association between activating transcription factor 3 and chronic liver diseases

Funds: 

Key R & D Projects of Sichuan Provincial Department of Science and Technology 20ZDYF2153

  • 摘要: 转录激活因子3(ATF3)属于转录因子ATF/ CREB家族的成员, 是一种适应反应基因, 参与多种细胞活动的调控以适应细胞内外环境的变化。近年来研究发现, ATF3可通过调节糖异生、脂肪代谢、免疫功能等在非酒精性脂肪性肝病、肝纤维化、肝癌等多种肝脏疾病进展中发挥关键作用。就ATF3在肝脏疾病中的作用机制研究进展进行了概述。

     

  • [1] HAI T, WOLFORD CC, CHANG YS. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: Is modulation of inflammation a unifying component?[J]. Gene Expr, 2010, 15(1): 1-11. DOI: 10.3727/105221610x12819686555015.
    [2] ROHINI M, HARITHA MENON A, et al. Role of activating transcription factor 3 and its interacting proteins under physiological and pathological conditions[J]. Int J Biol Macromol, 2018, 120(Pt A): 310-317. DOI: 10.1016/j.ijbiomac.2018.08.107.
    [3] UDAYAKUMAR TS, STOYANOVA R, SHAREEF MM, et al. Edelfosine promotes apoptosis in androgen-deprived prostate tumors by increasing ATF3 and inhibiting androgen receptor activity[J]. Mol Cancer Ther, 2016, 15(6): 1353-1363. DOI: 10.1158/1535-7163.MCT-15-0332.
    [4] JOO JH, UEDA E, BORTNER CD, et al. Farnesol activates the intrinsic pathway of apoptosis and the ATF4-ATF3-CHOP cascade of ER stress in human T lymphoblastic leukemia Molt4 cells[J]. Biochem Pharmacol, 2015, 97(3): 256-268. DOI: 10.1016/j.bcp.2015.08.086.
    [5] CHUEH AC, TSE J, IOANNIDIS P, et al. Abstract 4728: Histone deacetylase inhibitors induce apoptosis in multiple tumor types through induction of ATF3[J]. Cancer Res, 2016, 76(14): 4728-4728. DOI: 10.1158/1538-7445.
    [6] ZHAO J, LI X, GUO M, et al. The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation[J]. BMC Genomics, 2016, 17: 335. DOI: 10.1186/s12864-016-2664-8.
    [7] FUKASAWA K, PARK G, IEZAKI T, et al. ATF3 controls proliferation of osteoclast precursor and bone remodeling[J]. Sci Rep, 2016, 6: 30918. DOI: 10.1038/srep30918.
    [8] JEONG BC, KIM JH, KIM K, et al. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins[J]. Bone, 2017, 95: 33-40. DOI: 10.1016/j.bone.2016.11.005.
    [9] WANG Z, YAN C. Emerging roles of ATF3 in the suppression of prostate cancer[J]. Mol Cell Oncol, 2016, 3(1): e1010948. DOI: 10.1080/23723556.2015.1010948.
    [10] GUO N, MENG C, BAI W, et al. Prostaglandin F2α induces expression of activating transcription factor 3 (ATF3) and activates MAPK signaling in the rat corpus luteum[J]. Acta Histochem, 2015, 117(2): 211-218. DOI: 10.1016/j.acthis.2014.12.008.
    [11] JE YJ, CHOI DK, SOHN KC, et al. Inhibitory role of Id1 on TGF-β-induced collagen expression in human dermal fibroblasts[J]. Biochem Biophys Res Commun, 2014, 444(1): 81-85. DOI: 10.1016/j.bbrc.2014.01.010.
    [12] GOKULNATH M, PARTRIDGE NC, SELVAMURUGAN N. Runx2, a target gene for activating transcription factor-3 in human breast cancer cells[J]. Tumour Biol, 2015, 36(3): 1923-1931. DOI: 10.1007/s13277-014-2796-x.
    [13] KU HC, CHENG CF. Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer[J]. Front Endocrinol (Lausanne), 2020, 11: 556. DOI: 10.3389/fendo.2020.00556.
    [14] ALLEN-JENNINGS AE, HARTMAN MG, KOCIBA GJ, et al. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas[J]. J Biol Chem, 2001, 276(31): 29507-29514. DOI: 10.1074/jbc.M100986200.
    [15] ALLEN-JENNINGS AE, HARTMAN MG, KOCIBA GJ, et al. The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression[J]. J Biol Chem, 2002, 277(22): 20020-20025. DOI: 10.1074/jbc.M200727200.
    [16] KIM JY, SONG EH, LEE HJ, et al. Chronic ethanol consumption-induced pancreatic {beta}-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation[J]. J Biol Chem, 2010, 285(48): 37251-37262. DOI: 10.1074/jbc.M110.142315.
    [17] JANG MK, PARK HJ, JUNG MH. ATF3 represses PDX-1 expression in pancreatic β-cells[J]. Biochem Biophys Res Commun, 2011, 412(2): 385-390. DOI: 10.1016/j.bbrc.2011.07.108.
    [18] TSAI WW, MATSUMURA S, LIU W, et al. ATF3 mediates inhibitory effects of ethanol on hepatic gluconeogenesis[J]. Proc Natl Acad Sci U S A, 2015, 112(9): 2699-2704. DOI: 10.1073/pnas.1424641112.
    [19] KIM JY, LEE SH, SONG EH, et al. A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: Controlled by ATF3[J]. Cell Signal, 2009, 21(12): 1758-1767. DOI: 10.1016/j.cellsig.2009.07.011.
    [20] JANG MK, SON Y, JUNG MH. ATF3 plays a role in adipocyte hypoxia-mediated mitochondria dysfunction in obesity[J]. Biochem Biophys Res Commun, 2013, 431(3): 421-427. DOI: 10.1016/j.bbrc.2012.12.154.
    [21] JANG MK, KIM CH, SEONG JK, et al. ATF3 inhibits adipocyte differentiation of 3T3-L1 cells[J]. Biochem Biophys Res Commun, 2012, 421(1): 38-43. DOI: 10.1016/j.bbrc.2012.03.104.
    [22] JANG MK, JUNG MH. ATF3 represses PPARγ expression and inhibits adipocyte differentiation[J]. Biochem Biophys Res Commun, 2014, 454(1): 58-64. DOI: 10.1016/j.bbrc.2014.10.028.
    [23] CHENG CF, KU HC, CHENG JJ, et al. Adipocyte browning and resistance to obesity in mice is induced by expression of ATF3[J]. Commun Biol, 2019, 2: 389. DOI: 10.1038/s42003-019-0624-y.
    [24] KIM S, SONG NJ, BAHN G, et al. ATF3 induction is a therapeutic target for obesity and metabolic diseases[J]. Biochem Biophys Res Commun, 2018, 504(4): 903-908. DOI: 10.1016/j.bbrc.2018.09.048.
    [25] LIU YF, WEI JY, SHI MH, et al. Glucocorticoid induces hepatic steatosis by inhibiting activating transcription factor 3 (ATF3)/S100A9 protein signaling in granulocytic myeloid-derived suppressor cells[J]. J Biol Chem, 2016, 291(41): 21771-21785. DOI: 10.1074/jbc.M116.726364.
    [26] de NARDO D, LABZIN LI, KONO H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3[J]. Nat Immunol, 2014, 15(2): 152-160. DOI: 10.1038/ni.2784.
    [27] ROSENBERGER CM, CLARK AE, TREUTING PM, et al. ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells[J]. Proc Natl Acad Sci U S A, 2008, 105(7): 2544-2549. DOI: 10.1073/pnas.0712182105.
    [28] HOETZENECKER W, ECHTENACHER B, GUENOVA E, et al. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression[J]. Nat Med, 2011, 18(1): 128-134. DOI: 10.1038/nm.2557.
    [29] ZHU Q, WANG H, JIANG B, et al. Loss of ATF3 exacerbates liver damage through the activation of mTOR/p70S6K/ HIF-1α signaling pathway in liver inflammatory injury[J]. Cell Death Dis, 2018, 9(9): 910. DOI: 10.1038/s41419-018-0894-1.
    [30] KIM JY, PARK KJ, HWANG JY, et al. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis[J]. J Hepatol, 2017, 67(2): 349-359. DOI: 10.1016/j.jhep.2017.03.023.
    [31] FANG J, JI YX, ZHANG P, et al. Hepatic IRF2BP2 mitigates nonalcoholic fatty liver disease by directly repressing the transcription of ATF3[J]. Hepatology, 2020, 71(5): 1592-1608. DOI: 10.1002/hep.30950.
    [32] TU C, XIONG H, HU Y, et al. Cardiolipin synthase 1 ameliorates NASH through activating transcription factor 3 transcriptional inactivation[J]. Hepatology, 2020, 72(6): 1949-1967. DOI: 10.1002/hep.31202.
    [33] SHI Z, ZHANG K, CHEN T, et al. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells[J]. Cell Death Dis, 2020, 11(12): 1066. DOI: 10.1038/s41419-020-03271-6.
    [34] LI XY, ZANG SB, ZHANG Y, et al. Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance[J]. Pathol Res Pract, 2014, 210(8): 477-481. DOI: 10.1016/j.prp.2014.03.013.
    [35] WANG ZX, YIN SN, TIAN G, et al. Activating transcription factor 3 is downregulated in hepatocellular carcinoma and functions as a tumor suppressor by regulating cyclin D1[J]. Open Life Sci, 2016, 11(1): 367-371. DOI: 10.1515/biol-2016-0048.
    [36] LI X, ZANG S, CHENG H, et al. Over expression of activating transcription factor 3 exerts suppressive effects in HepG2 cells[J]. Mol Med Rep, 2019, 19(2): 869-876. DOI: 10.3892/mmr.2018.9707.
    [37] CHEN C, GE C, LIU Z, et al. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression[J]. J Exp Clin Cancer Res, 2018, 37(1): 263. DOI: 10.1186/s13046-018-0919-8.
    [38] SHEN J, LIN H, LI G, et al. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth[J]. Oncotarget, 2016, 7(22): 32088-32099. DOI: 10.18632/oncotarget.8525.
    [39] WENG S, ZHOU L, DENG Q, et al. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in hepatocellular carcinoma cells[J]. BMC Gastroenterol, 2016, 16: 25. DOI: 10.1186/s12876-016-0442-3.
    [40] LIN L, YAO Z, BHUVANESHWAR K, et al. Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2[J]. Carcinogenesis, 2014, 35(11): 2393-2403. DOI: 10.1093/carcin/bgu163.
  • 加载中
计量
  • 文章访问数:  32
  • HTML全文浏览量:  6
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-03
  • 修回日期:  2021-02-23
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回